PolyPid

Executive Summary

PolyPid is an Israeli biopharmaceutical company leveraging its proprietary Kynatrix™ platform to develop long-acting, controlled-release therapies. The technology enables zero-burst, localized delivery of APIs, with a primary focus on preventing surgical site infections (SSI) via its lead candidate D-PLEX. The company also has early-stage programs in metabolic disease and oncology. PolyPid is currently in Phase 3 development for D-PLEX, targeting a large unmet need in SSI prophylaxis. With a differentiated drug delivery approach and a clear clinical path, PolyPid represents a mid-stage investment opportunity in the surgical care and drug delivery space. Key upcoming milestones include the readout of its Phase 3 trial for D-PLEX in SSI prevention, which could serve as a major value inflection point. Positive results would support regulatory filings in the US and EU, while a partnership or licensing deal could de-risk commercialization. The company's platform also holds potential for pipeline expansion beyond lead indications. Investors should monitor trial data and strategic collaborations as near-term catalysts.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 D-PLEX Top-line Data55% success
• 2027Regulatory Submission (NDA/MAA) for D-PLEX40% success
• 2026Partnership or Licensing Deal for D-PLEX or Platform30% success